Editorials

Osteoarthritis, Exercise, and Knee Replacement
J.F. Fries, B. Bruce, S. Shoor ........................................ 669
Exercise and Osteoarthritis: Not Necessarily an All-or-Nothing Proposition!
A.C. Gelber .................................................. 672
Anti-Citrullinated Peptide/Protein Antibodies and Structural Prognosis of Rheumatoid Arthritis: Quantity Versus Quality
O. Meyer .................................................... 675
Fibromyalgia and Enthesitis in Psoriatic Arthritis. Time to “Characterize” and “Refine” Clinical Definitions
J.L. Fernández-Sueiro ........................................... 677

Reviews

Apoptosis as a Mechanism of Action of TNF Antagonists in Rheumatoid Arthritis
D. Makrygiannakis, A.I. Catrina .................................... 679
Relationship Between ACE Insertion/Deletion Gene Polymorphism and SLE/Lupus Nephritis: A Systematic Review and Metaanalysis
T-B. Zhou, Y-G. Liu, N. Lin, Y-H. Qin, K. Huang, M-B. Shao, D-D. Peng ........................................ 686

Articles

ACPA, But Not Its Titer, Is a Predictor of Radiographic Progression and Disease Activity in RA
K. Shiozawa, Y. Kawasaki, T. Yamane, R. Yoshihara, Y. Tanaka, K. Uto, S. Shiozawa ........................................ 694
Infliximab Treatment Increases LVEF in Patients with RA: Assessment of Heart Function by Echocardiography, ET-1, IL-6, and NT-pro Brain Natriuretic Peptide
P.J. Kotyla, A. Owczarek, J. Rakocyzy, M. Lewicki, E.J. Kucharz, P. Emery ........................................ 701
Time to Consultation and DMARD Treatment of Patients with RA — Northern Alberta Perspective
Short-term Risk of Total Malignancy and Nonmelanoma Skin Cancers with Certolizumab and Golimumab in Patients with RA: Metaanalysis of Randomized Controlled Trials
P. Le Blay, G. Mouterde, T. Barnetche, J. Morel, B. Combe ........................................ 712
Characterization of Patients with Arthritis Referred for Gold Therapy in the Era of Biologics
J.M. Cheung, D. Scarsbrook, A.V. Klinkhoff ........................................ 716
Efficacy and Safety of CE-224,535, an Antagonist of P2X Receptor, in Treatment of Patients with RA Inadequately Controlled by MTX
T.C. Stock, B.J. Bloom, N. Wei, S. Ishaq, W. Park, X. Wang, et al ........................................ 720
CRP Is a More Sensitive and Specific Marker for Diagnosing Bacterial Infections in SLE Compared to S100A8/A9 and Procalcitonin
Construct and Criterion Validity of the Short Form-6D Utility Measure in Patients with SLE
Occupational Risk Factors for SLE: A Nationwide Study Based on Hospitalizations in Sweden
X. Li, J. Sundquist, K. Sundquist, B. Zöller ........................................ 743
Blood Pressure and Vascular Dysfunction Underlie Elevated Cerebral Blood Flow in SLE
Differences between Male and Female SLE in a Multiethnic Population
T.C. Tan, H. Fang, L.S. Magder, M.A. Petri ........................................ 759
Are Cognitive and Olfactory Dysfunctions in NPSLE Dependent on Anxiety or Depression?
Low Socioeconomic Status Is Associated with Cardiovascular Risk Factors and Outcomes in SLE
J.W. Maynard, H. Fang, M.A. Petri ........................................ 777
Epidemiology of SSc in a Large US Managed Care Population
D.E. Furst, A.W. Fernandes, Ş.R. Iorga, W. Greth, T. Bancroft ........................................ 784
Clinical Correlates of CENP-A and CENP-B Antibodies in a Large Cohort of Patients with SSc
Patient-reported Outcomes in Polymyalgia Rheumatica
Detection of HTLV-1 in the Labial Salivary Glands of Patients with Sjögren’s Syndrome: A Distinct Clinical Subgroup?